From the publishers of JADPRO

Bone Protection Resource Center

Advertisement

Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer

In a cohort study of 54,953 older men with prostate cancer, only 7.9% received dual-energy x-ray absorptiometry (DXA) screening within 12 months before and 6 months after beginning  androgen-deprivation therapy. However, testing of bone mineral density with DXA was significantly associated with a decreased risk of developing major osteoporotic fractures (HR, 0.91; 95% CI, 0.83-1.00; P = .05) after adjusting for propensity score.

JAMA Open Network
Advertisement
News & Literature Highlights

Cells

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Current Osteoporosis Reports

Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies

JAMA Network Open

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Journal of the National Comprehensive Cancer Network

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Annals of Pharmacotherapy

Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

JAMA Open Network

Description of Major Osteoporotic Fractures in Women With Invasive Breast Cancer Who Received Endocrine Therapy

JAMA Open Network

Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma

Journal of Bone Oncology

Bone Metastases From Urothelial Carcinoma. The Dark Side of the Moon

Metabolism

Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials

Journal of Clinical Oncology

Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update

Advertisement
Advertisement